Group Calls for 2 Arthritis Drug Bans
Public Citizen Says Celebrex, Bextra Share Vioxx's Problems
Jan. 24, 2005 -- A pharmaceutical watchdog group called on federal
regulators Monday to ban two prescription pain relief medications similar to
Vioxx, saying the drugs increase the risk of heart attacks and other
Public Citizen filed a petition with the FDA asking the agency to
immediately remove Celebrex and Bextra from the market. Celebrex and Bextra are
two arthritis drugs in a class known as Cox-2 inhibitors. According to the
group, Americans filled more than 36 million prescriptions of these drugs last
Public Citizen is a longtime critic of both the pharmaceutical industry and
the FDA, and it independently warned patients more than four years ago that
Celebrex was unsafe.
The group said Monday that studies show that Celebrex and Bextra increase
the likelihood of dangerous heart problems while offering patients little or no
benefit over older pain relievers.
"Both drugs are fundamentally dangerous, and the only way of dealing
with that is to get them off the market," Sidney Wolfe, MD, head of Public
Citizen's Health Research Group, tells WebMD.
Wolfe says the group does not have data suggesting how many adverse health
events may have resulted from the use of the two drugs.
Similar Drug Pulled From Market
The petition comes after Merck & Co. voluntarily pulled Vioxx from the
market in September 2004 following reports of increased heart attack risk in
patients taking it. The move prompted some experts to speculate that the side
effects are not unique to Vioxx but could be shared by the entire class of
Cox-2 inhibitor drugs.
FDA scientist David Graham, MD, singled out Bextra and four other
prescription drugs as potentially unsafe in November 2004 when he testified in
front of the Senate Finance Committee about drug safety problems at the
Cox-2 inhibitors are widely used in patients with joint pain because they
generally avoid the risk of stomach bleeding caused by nonsteroidal
anti-inflammatory drugs like ibuprofen.
In one study published in 2000, researchers found that patients taking
Celebrex had a slightly higher chance of developing chest pain (angina) than
those taking ibuprofen. The study findings did not reach mathematical
significance, meaning the results could have been by chance. However, FDA
scientists at the time cited a "consistent and worrisome trend" in
several studies pointing to cardiovascular toxicity caused by the drug.
At the same time, the study, known as CLASS, found no difference in the rate
of serious stomach or intestinal complications in patients who took Celebrex or
ibuprofen, according to Public Citizen's complaint.
Then, in December 2004, the National Institutes of Health abruptly halted a
colon polyp study after preliminary data suggested that patients taking
Celebrex were up to 3.4 times more likely than those taking a placebo to have a
heart attack, stroke, or a sudden, heart-related death.